Phenomix Sciences is a precision obesity biotechnology company on a mission to conquer obesity globally through the use of our proprietary genetic tests, unique data sets, and advanced analytics. Mayo Clinic physicians, scientists, and researchers, Andres Acosta, M.D. Ph.D., and Michael Camilleri, M.D. D.Sc., founded the company after 10 years of rigorous clinical research focused on uncovering the pathophysiology behind the variability in response to obesity treatments. Phenomix believes that the key to understanding obesity is its unprecedented access to clinical and molecular information throughout all stages and phenotypes of the disease. Phenomix leverages data intelligence for yielding better accuracy in predicting individual patient response to specific weight loss interventions and reducing the variability in weight loss results for patients.
Date | Amount | Type | Investors | Valuation |
---|---|---|---|---|
05/16/24 | $5,500,000 | Series A |
Dexcom Ventures Health 2047 Capital Partners LabCorp | undisclosed |